THE NHSN TARGETED ASSESSMENT FOR ANTIMICROBIAL STEWARDSHIP (TAS)

NHSN AUR Team

September 2022

What is the TAS framework?

- Quality improvement tool developed by CDC using NHSN AU Option.
  - Adapted from CDC's Targeted Assessment for Prevention (TAP) Strategy

- Available to all hospitals participating in the NHSN AU Option.

- Used by antimicrobial stewards at individual facilities and group function (health departments and health systems).

CDC's TAP Strategy: https://www.cdc.gov/hai/prevent/tap.html

Why was the TAS framework developed?

- AU Users have been asking us for NHSN analytic support in helping meet their facility-identified SAAR targets
  - "We came up with a SAAR goal of 0.9, how many days of therapy do we need to eliminate to get there?"

- AU users can input a prevention target (for example, SAAR = 0.9) and the application will tell them how many DOTs need to be reduced to meet their target.

The TAS framework consists of three components:

1. **Target:** Run TAS Reports in NHSN to identify facilities, location groups and locations for further assessment using the ranked **AU cumulative attributable difference (AU-CAD)**.

2. **Assess:** Utilize assessment tools to identify gaps and opportunities to improve antibiotic use.

3. **Steward:** Implement antibiotic stewardship activities to address gaps and opportunities.

What is the AU-cumulative attributable difference (AU-CAD)?

- The AU-CAD value translates the SAAR target into a tangible number of antimicrobial days to reduce or add to achieve a SAAR target.

AU-CAD = Observed antimicrobial days - (Predicted antimicrobial days x SAAR target)

AU-cumulative attributable difference (AU-CAD)

AU-CAD = **Observed antimicrobial days** - (Predicted antimicrobial days x SAAR target)

Observed antimicrobials days: Antimicrobial days reported by a facility for a SAAR antimicrobial agent category in a specified patient care location, group of locations, or group of facilities.

AU-cumulative attributable difference (AU-CAD)

AU-CAD = Observed antimicrobial days - (**Predicted antimicrobial days** x SAAR target)

Predicted antimicrobials days: Antimicrobial days predicted for that same antimicrobial agent category calculated using risk-adjusted SAAR predictive models.

AU-cumulative attributable difference (AU-CAD)

AU-CAD = Observed antimicrobial days - (Predicted antimicrobial days x **SAAR target**)

SAAR target: SAAR target chosen by AU users for each antimicrobial agent category

How do I interpret the AU-CAD value?

- Like the SAAR, the AU-CAD is not a measure of the appropriateness
  - Stewards will need to evaluate the appropriateness of AU for select antibiotics or infections to inform the clinical relevance of AU-CAD reductions or additions.

- A *positive* AU-CAD value represents the number of antimicrobial days that should be *reduced* to *decrease* the SAAR value and reach the SAAR target.

- A *negative* AU-CAD value represents the number of antimicrobial days to *add* to *increase* the SAAR value and reach the SAAR target.

An example in interpreting the AU-CAD value

AU-CAD = Observed antimicrobial days - (Predicted antimicrobial days x **0.95**)

- If a facility has an AU-CAD of 75 when they run a TAS report with a SAAR target of 0.95, the interpretation would be "The facility would have needed 75 fewer antimicrobial days to reach their SAAR target of 0.95 during this time period."

How do I select a SAAR target?

Modify "TAS Report - Adult SAAR Types - Facility"

☑ Show descriptive variable names (Print List)

| Title/Format | Time Period | Filters | **Display Options** ①|

TAS Options:

Group by: Cumulative ▾

Population: Adult ▾ ②

All Antibacterials [1]
BSHO [1]
BSCA [1]
GramPos [1]   ③
NSBL [1]
CDI [1]
Antifungal [1]

Reset **Save** ④

- Unlike the HAI Targeted Assessment for Prevention (TAP) Strategy and SIRs, there are no national SAAR goals.

- The SAAR target values may differ by facility based upon factors such as:
  - Original SAAR value
  - Stewardship priorities
  - Clinical relevance (for example, findings from MUE)

CDC's TAP Strategy: https://www.cdc.gov/hai/prevent/tap.html

T Target **A** Assess **S** Steward

National SAAR distributions can help facilities identify SAAR target

- AU users can identify their **SAAR percentile** within the NHSN SAAR Reports for a given location.

Broad spectrum antibacterial agents predominantly used for hospital-onset infections used in adult SAAR wards

Facility Org ID	SAAR Type 2017 Baseline	Location	Summary Year/Month	CDC Location	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	SAAR p-value	95% Confidence Interval	SAAR Percentile
10009	Adult_BSHO_Ward_2017	MEDSURG64	2022M01	IN:ACUTE:WARD:MS	45	36.819	320	1.222	0.1852	0.902, 1.621	64

Example data

National SAAR distributions can help facilities identify SAAR target

- After identifying your **SAAR percentile**, you can use the SAAR distributions provided in the NHSN AU Data Reports to determine your **SAAR target** as clinically appropriate.

	A	F	G	H	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB
1	**Table 2b. Adult broad spectrum antibacterial agents predominantly used for hospital-onset infections (Adult BSHO)**																						
2																							
3	**Table 2b1:** Adult BSHO SAAR distributions, by SAAR location type																						
4		SAAR and 95% confidence limits (CL)			Percentile distribution of location-specific SAARs																		
5	**Adult SAAR location type**	**SAAR**	**Lower CL**	**Upper CL**	**5th**	**10th**	**15th**	**20th**	**25th**	**30th**	**35th**	**40th**	**45th**	**50th**	**55th**	**60th**	**65th**	**70th**	**75th**	**80th**	**85th**	**90th**	**95th**
10	Medical-surgical wards	1.065	1.063	1.066	0.329	0.472	0.571	0.655	0.722	0.794	0.867	0.936	0.996	1.052	1.109	1.168	1.233	1.286	1.357	1.442	1.533	1.666	1.881
14	Adult BSHO drugs: Amikacin (IV only), Aztreonam (IV only), Cefepime, Ceftazidime, Doripenem, Gentamicin (IV only), Imipenem with Cilastatin, Meropenem, Piperacillin with Tazobactam, Tobramycin (IV only)																						

AU Data Reports: https://www.cdc.gov/nhsn/datastat/aur-reports.html

NHSN Group Users may use several approaches to set SAAR targets

- Each state health department may use different SAAR targets

  – State-specific SAAR values in the Antibiotic Resistance and Patient Safety Portal can inform the SAAR targets

- Other group users may set different SAAR targets for the highest quartile compared to the other quartiles of facilities within the group.

Antibiotic Resistance and Patient Safety Portal: https://arpsp.cdc.gov/profile/inpatient-antibiotic-use/all

The TAS framework is a dynamic process

Stewards may explore setting different SAAR targets and evaluate the clinical feasibility of each value, before deciding on the most appropriate final SAAR target.

TAS Reports – Overview

Amy Webb

Who can generate the TAS Reports?

- Facility must:
  - AU data submitted for at least 1 of the most recent 12 months
    - At least 1 location that can generate SAARs (see screenshot)
- User must:
  - Have analysis rights
  - Generated data sets since 9/9/22

Location Group in TAS Reports	CDC Location Type	CDC Location Code
Adult Locations		
ICU	Medical Critical Care	IN:ACUTE:CC:M
ICU	Surgical Critical Care	IN:ACUTE:CC:S
ICU	Medical-Surgical Critical Care	IN:ACUTE:CC:MS
Stepdown	Adult Step Down Unit	IN:ACUTE:STEP
Ward	Medical Ward	IN:ACUTE:WARD:M
Ward	Surgical Ward	IN:ACUTE:WARD:S
Ward	Medical-Surgical Ward	IN:ACUTE:WARD:MS
Oncology	ONC General Hematology-Oncology Ward	IN:ACUTE:WARD:ONC_HONC
Pediatric Locations		
ICU	Pediatric Medical Critical Care	IN:ACUTE:CC:M:PED
ICU	Pediatric Medical-Surgical Critical Care	IN:ACUTE:CC:MS_PED
Ward	Pediatric Medical Ward	IN:ACUTE:WARD:M_PED
Ward	Pediatric Surgical Ward	IN:ACUTE:WARD:S_PED
Ward	Pediatric Medical-Surgical Ward	IN:ACUTE:WARD:MS_PED
Neonatal Locations		
N/A	Step down Neonatal Nursery	IN:ACUTE:STEP:NURS
N/A	Neonatal Critical Care (Level II/III)	IN:ACUTE:CC_STEP:NURS
N/A	Neonatal Critical Care (Level III)	IN:ACUTE:CC:NURS
N/A	Neonatal Critical Care (Level IV)	IN:ACUTE:CC:NURS_IV

Where can I find the TAS Reports in NHSN?

1. Analysis → Generate data sets
   a) Leave beginning and ending dates blank
2. Analysis → Reports
   a) AUR Module → TAS Reports

How to generate datasets:
https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/generatedatasets-psc-508.pdf

Why are there so many TAS Reports?

- Reports for each population: Adult, Pediatric, Neonatal

Why are there so many TAS Reports? (cont.)

- Reports for each population: Adult, Pediatric, Neonatal
- Reports for various levels of aggregation:
    - Group (available for NHSN Groups)
    - Facility
    - Location Group
        - ICUs, Wards, Stepdown, Oncology
    - Location

Reports by level of aggregation

*Facility view

Reports by level of aggregation

*Facility view

Reports by level of aggregation

*Facility view

How do I enter SAAR targets?

- Click any TAS report then click Modify Report

1. Click Display Options

2. Note the population

3. Enter each SAAR target value

4. After entering the targets click Save

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**
- Do I need to set SAAR targets for each individual TAS report (for example, facility level report v. location level report)? **No**

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**

- Do I need to set SAAR targets for each individual TAS report (for example, facility level report v. location level report)? **No**

- Can I set different SAAR targets for different locations (MedWard v SurgWard) or location groups (ICU v Ward)? **No**

  – Can I set different SAAR targets for different facilities in my NHSN Group? **No**

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**

- Do I need to set SAAR targets for each individual TAS report (for example, facility level report v. location level report)? **No**

- Can I set different SAAR targets for different locations (MedWard v SurgWard) or location groups (ICU v Ward)? **No**

- Do my SAAR targets need to all be the same value (for example, 1.0) across all SAAR Types? **No**

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**

- Do I need to set SAAR targets for each individual TAS report (for example, facility level report v. location level report)? **No**

- Can I set different SAAR targets for different locations (MedWard v SurgWard) or location groups (ICU v Ward)? **No**

- Do my SAAR targets need to all be the same value (for example, 1.0) across all SAAR Types? **No**

- When I change my SAAR targets, does it affect other users' SAAR targets? **No**

More about SAAR targets

- Can I change my SAAR targets after I set them? **Yes**

- Do I need to set SAAR targets for each individual TAS report (for example, facility level report v. location level report)? **No**

- Can I set different SAAR targets for different locations (MedWard v SurgWard) or location groups (ICU v Ward)? **No**

- Do my SAAR targets need to all be the same value (for example, 1.0) across all SAAR Types? **No**

- When I change my SAAR targets, does it affect other users' SAAR targets? **No**

- Can anyone else see my SAAR targets? **No**

Important reminders

- TAS reports only include:
  - Data uploaded for the most recent 12 months
    - Example: When generating the TAS reports today (9/27), they will include all AU data uploaded for Sept 2021 – Aug 2022
    - **Generate new data sets to include recently uploaded data**

  - Locations that can generate SAARs
    - **No "facility-wide" metrics available in TAS reports & dashboard**

TAS Reports – Facility Level

Amy Webb

An example

- The TAS Reports have just been introduced in NHSN.
- Let's explore the reports with a SAAR target of 1.0.

Facility Level TAS Report Output

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAAR TypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

1. Tables include the most recent 12 months of reported data from locations for which SAARs are generated. If SAAR Type-level AU-CADs are the same, their ranks are tied.

2. AU-CAD = Observed Antimicrobial Days - (Predicted Antimicrobial Days * Facility Identified SAAR Target)

3. When selecting a SAAR Target, consider the lower bound of the SAAR Confidence Interval. See the TAS User Guide for further details.

4. A negative AU-CAD value means the SAAR Target was greater than the current SAAR value for that category. To increase your SAAR value, the negative AU-CAD value represents the number of antimicrobial days to add per time period to reach your SAAR Target.

5. The drug code and full drug name can be found here: http://www.cdc.gov/nhsn/xls/aur/aur-eligible-antimicrobial-agents.xlsx.

6. If the observed antimicrobial days exceed days present for a specific SAAR category, neither the SAAR nor the AU-CAD will be calculated, and data should be validated for accuracy.

Source of aggregate data: 2017 NHSN SAAR Data

This example uses fictitious data for illustrative purposes only.

Header & Footnotes

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAAR TypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

1. Tables include the most recent 12 months of reported data from locations for which SAARs are generated. If SAAR Type-level AU-CADs are the same, their ranks are tied.

2. AU-CAD = Observed Antimicrobial Days - (Predicted Antimicrobial Days * Facility Identified SAAR Target)

3. When selecting a SAAR Target, consider the lower bound of the SAAR Confidence Interval. See the TAS User Guide for further details.

4. A negative AU-CAD value means the SAAR Target was greater than the current SAAR value for that category. To increase your SAAR value, the negative AU-CAD value represents the number of antimicrobial days to add per time period to reach your SAAR Target.

5. The drug code and full drug name can be found here: http://www.cdc.gov/nhsn/xls/aur/aur-eligible-antimicrobial-agents.xlsx.

6. If the observed antimicrobial days exceed days present for a specific SAAR category, neither the SAAR nor the AU-CAD will be calculated, and data should be validated for accuracy.

Source of aggregate data: 2017 NHSN SAAR Data

This example uses fictitious data for illustrative purposes only.

SAAR Type Category

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- Each Adult SAAR Type is listed
  - SAAR Type abbreviations:
    https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf

This example uses fictitious data for illustrative purposes only.

Familiar things – SAAR Report variables

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- **Reminder!** Will include all locations that can generate SAARs within the population (for example, Adult SAAR locations)

This example uses fictitious data for illustrative purposes only.

New things – TAS variables

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAAR TypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- **Reminder!** Will include all locations that can generate SAARs within the population (for example, Adult SAAR locations)

This example uses fictitious data for illustrative purposes only.

SAAR Types displayed by AU-CAD Rank

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- Highest Facility AU-CAD value ranked #1
- Ranks tied if AU-CAD value is tied

This example uses fictitious data for illustrative purposes only.

Facility AU-CAD uses observed, predicted & SAAR target

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- AU-CAD = Observed antimicrobial days – (Predicted antimicrobial days x SAAR target
  - NSBL AU-CAD = 5706 – (4462.067 x 1.0)
  - NSBL AU-CAD ≈ 1244

This example uses fictitious data for illustrative purposes only.

Facility AU-CAD interpretation

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA [...]ntifungal = (1)

As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

To get to an NSBL SAAR of 1.0, the facility would have needed to reduce the use of antimicrobials in the NSBL category by roughly 1244 antimicrobial days over the last 12 months.

Facility Org ID	Facility Name	SAAR TypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- AU-CAD = Observed antimicrobial days – (Predicted antimicrobial days x SAAR target)
  - NSBL AU-CAD = 5706 – (4462.067 x 1.0)
  - NSBL AU-CAD ≈ 1244

This example uses fictitious data for illustrative purposes only.

Three Highest Use Drugs

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAAR TypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

- Three highest use drugs and their percentages <u>within</u> each SAAR type

  - Example: $\dfrac{AMOX\ antimicrobial\ days}{All\ NSBL\ antimicrobial\ days}$ x 100 = $\dfrac{456\ AMOX\ days}{5706\ NSBL\ days}$ x 100 = 8%

Drug code abbreviations: https://www.cdc.gov/nhsn/xls/aur/aur-eligible-antimicrobial-agents.xlsx

This example uses fictitious data for illustrative purposes only.

Reassessing SAAR targets

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

This example uses fictitious data for illustrative purposes only.

Updated SAAR targets

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (1); BSHO = (1); BSCA = (1); GramPos = (1); NSBL = (1); CDI = (1); Antifungal = (1)
As of: September 26, 2022 at 9:44 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	1	1244	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		ANTIFGL	2	-229	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSCA	3	-2958	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		GRAMPOS	4	-2987	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		CDI	5	-5368	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		BSHO	6	-7964	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267
		ALL	7	-11376	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703

NSBL 1.1
CDI 0.45
Antifungal 0.8

Reset Save

This example uses fictitious data for illustrative purposes only.

TAS Report output with new targets

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Facility
Adult SAAR Types Ranked by AU-CAD
Facility Identified SAAR Targets: All antibacterials = (0.65); BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)

As of: September 26, 2022 at 10:33 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Org ID	Facility Name	SAARTypeCat	AU-CAD Rank	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	ALL	1	1668	AMOX(2); CEFTAZ(2); MINO(2);	25893	37269.485	52759	0.695	0.686, 0.703
		NSBL	2	798	AMOX(8); CEFOX(8); AMOXWC(7);	5706	4462.067	52759	1.279	1.246, 1.312
		GRAMPOS	3	517	QUINWD(13); CEFTAR(12); TELAV(12);	3385	6372.250	52759	0.531	0.514, 0.549
		BSCA	4	374	ERTA(8); GEMIF(8); MOXI(8);	5371	8328.744	52759	0.645	0.628, 0.662
		CDI	5	355	CEFTAZ(9); GEMIF(9); MOXI(9);	5037	10404.835	52759	0.484	0.471, 0.498
		ANTIFGL	6	150	CASPO(26); ANID(26); FLUCO(25);	1665	1893.515	52759	0.879	0.838, 0.922
		BSHO	7	77	CEFTAZ(17); CEFEP(16); IMIPWC(16);	2757	10720.680	52759	0.257	0.248, 0.267

This example uses fictitious data for illustrative purposes only.

TAS Reports – Location Group Level

Amy Webb

Location Group report details

- Only available for Adult & Pediatric populations
- Two reports depending on your preferred sort:
  - Separated – Rank based on location group SAAR Type AU-CAD <u>within</u> the location group
  - Combined – Rank based on location group SAAR Type AU-CAD <u>among all</u> SAAR Types and location groups

Location Group in TAS Reports	CDC Location Type
Adult Locations	
ICU	Medical Critical Care
ICU	Surgical Critical Care
ICU	Medical-Surgical Critical Care
Stepdown	Adult Step Down Unit
Ward	Medical Ward
Ward	Surgical Ward
Ward	Medical-Surgical Ward
Oncology	ONC General Hematology-Oncology Ward
Pediatric Locations	
ICU	Pediatric Medical Critical Care
ICU	Pediatric Medical-Surgical Critical Care
Ward	Pediatric Medical Ward
Ward	Pediatric Surgical Ward
Ward	Pediatric Medical-Surgical Ward

Location Group TAS Report Output

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Location Groups (Separated)
Adult SAAR Types Location Groups Ranked by AU-CAD
Facility Identified SAAR Target: BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)
As of: September 26, 2022 at 10:50 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

FACILITY				LOCATION GROUP							
Facility Org ID	Facility Name	Facility AU-CAD (Rounded)	LocationGroup	SAARTypeCat	Location Group Rank	Location Group AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	1510	ICUS	BSCA	1	85	ERTA(9); CEFUR(9); GEMIF(8);	2764	4465.649	28864	0.619	0.596, 0.642
				NSBL	2	-19	AMOX(8); DICLOX(8); CTET(7);	3034	2775.785	28864	1.093	1.055, 1.132
				CDI	3	-188	CEFEP(10); CLIND(9); GEMIF(9);	2613	6223.497	28864	0.420	0.404, 0.436
				ANTIFGL	4	-313	FLUCO(28); CASPO(28); MICA(22);	887	1500.429	28864	0.591	0.553, 0.631
				GRAMPOS	5	-553	QUINWD(13); DALBA(13); TELAV(13);	1865	5372.512	28864	0.347	0.332, 0.363
				BSHO	6	-857	CEFEP(17); IMIPWC(16); MERO(15);	1475	9326.757	28864	0.158	0.150, 0.166
			STEPDOWN	NSBL	1	395	NAF(8); CEFAD(8); DICLOX(8);	1187	720.252	11538	1.648	1.556, 1.744
				GRAMPOS	2	160	TEDIZ(14); TELAV(14); DAPTO(13);	643	1072.986	11538	0.599	0.554, 0.647
				ANTIFGL	3	126	FLUCO(27); ANID(25); CASPO(25);	324	247.400	11538	1.310	1.173, 1.458
				BSHO	4	113	IMIPWC(17); MERO(16); CEFTAZ(15);	574	1844.385	11538	0.311	0.287, 0.337
				CDI	5	54	MOXI(10); CEFIX(10); CIPRO(9);	1020	2147.159	11538	0.475	0.447, 0.505
				BSCA	6	30	MOXI(9); CEFIX(9); CIPRO(9);	1090	1766.051	11538	0.617	0.581, 0.655
			WARDS	GRAMPOS	1	696	QUINWD(15); LNZ(13); ORITAV(13);	2060	3031.315	34168	0.680	0.651, 0.709
				ANTIFGL	2	533	ANID(29); CASPO(24); MICA(24);	1031	622.127	34168	1.657	1.558, 1.761
				BSHO	3	527	CEFTAZ(17); CEFEP(17); IMIPWC(16);	1652	4500.768	34168	0.367	0.350, 0.385
				CDI	4	323	CEFTAZ(9); CEFEP(9); MOXI(9);	3022	5997.117	34168	0.504	0.486, 0.522
				BSCA	5	56	MOXI(8); GEMIF(8); CEFPRO(8);	3252	5327.053	34168	0.610	0.590, 0.632
				NSBL	.	.	AMOX(94); CEFOX(1); CEFAZ(0);	53471	.	34168	.	.
			ONCOLOGY	NSBL	1	520	AMOXWC(9); NAF(8); AMPIWS(8);	1081	509.736	10866	2.121	1.997, 2.250
				GRAMPOS	2	177	QUINWD(16); CEFTAR(14); ORITAV(13);	632	1010.493	10866	0.625	0.578, 0.676
				BSCA	3	-6	CEFPO(9); ERTA(9); GEMIF(9);	1155	1935.253	10866	0.597	0.563, 0.632
				BSHO	4	-13	PIPERWT(18); IMIPWC(16); MERO(16);	496	2037.939	10866	0.243	0.223, 0.266
				CDI	5	-105	CEFPO(11); GEMIF(10); MOXI(9);	1033	2528.532	10866	0.409	0.384, 0.434
				ANTIFGL	6	-231	CASPO(27); ANID(26); FLUCO(25);	329	700.570	10866	0.470	0.421, 0.522

Facility AU-CAD is sum of location group AU-CADs

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Location Groups (Separated)
Adult SAAR Types Location Groups Ranked by AU-CAD
Facility Identified SAAR Target: BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)

As of: September 26, 2022 at 10:50 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

FACILITY					LOCATION GROUP						
Facility Org ID	Facility Name	Facility AU-CAD (Rounded)	LocationGroup	SAARTypeCat	Location Group Rank	Location Group AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	1510	ICUS	BSCA	1	85	ERTA(9); CEFUR(9); GEMIF(8);	2764	4465.649	28864	0.619	0.596, 0.642
				NSBL	2	-19	AMOX(8); DICLOX(8); CTET(7);	3034	2775.785	28864	1.093	1.055, 1.132
				CDI	3	-188	CEFEP(10); CLIND(9); GEMIF(9);	2613	6223.497	28864	0.420	0.404, 0.436
				ANTIFGL	4	-313	FLUCO(28); CASPO(28); MICA(22);	887	1500.429	28864	0.591	0.553, 0.631
				GRAMPOS	5	-553	QUINWD(13); DALBA(13); TELAV(13);	1865	5372.512	28864	0.347	0.332, 0.363
				BSHO	6	-857	CEFEP(17); IMIPWC(16); MERO(15);	1475	9326.757	28864	0.158	0.150, 0.166
			STEPDOWN	NSBL	1	395	NAF(8); CEFAD(8); DICLOX(8);	1187	720.252	11538	1.648	1.556, 1.744
				GRAMPOS	2	160	TEDIZ(14); TELAV(14); DAPTO(13);	643	1072.986	11538	0.599	0.554, 0.647
				ANTIFGL	3	126	FLUCO(27); ANID(25); CASPO(25);	324	247.400	11538	1.310	1.173, 1.458
				BSHO	4	113	IMIPWC(17); MERO(16); CEFTAZ(15);	574	1844.385	11538	0.311	0.287, 0.337
				CDI	5	54	MOXI(10); CEFIX(10); CIPRO(9);	1020	2147.159	11538	0.475	0.447, 0.505
				BSCA	6	30	MOXI(9); CEFIX(9); CIPRO(9);	1090	1766.051	11538	0.617	0.581, 0.655
			WARDS	GRAMPOS	1	696	QUINWD(15); LNZ(13); ORITAV(13);	2060	3031.215	34168	0.680	0.651, 0.709

Location Group TAS Report – Separated

FACILITY			LOCATION GROUP								
Facility Org ID	Facility Name	Facility AU-CAD (Rounded)	LocationGroup	SAARTypeCat	Location Group Rank	Location Group AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	1510	ICUS	BSCA	1	85	ERTA(9); CEFUR(9); GEMIF(8);	2764	4465.649	28864	0.619	0.596, 0.642
				NSBL	2	-19	AMOX(8); DICLOX(8); CTET(7);	3034	2775.785	28864	1.093	1.055, 1.132
				CDI	3	-188	CEFEP(10); CLIND(9); GEMIF(9);	2613	6223.497	28864	0.420	0.404, 0.436
				ANTIFGL	4	-313	FLUCO(28); CASPO(28); MICA(22);	887	1500.429	28864	0.591	0.553, 0.631
				GRAMPOS	5	-553	QUINWD(13); DALBA(13); TELAV(13);	1865	5372.512	28864	0.347	0.332, 0.363
				BSHO	6	-857	CEFEP(17); IMIPWC(16); MERO(15);	1475	9326.757	28864	0.158	0.150, 0.166
			STEPDOWN	NSBL	1	395	NAF(8); CEFAD(8); DICLOX(8);	1187	720.252	11538	1.648	1.556, 1.744
				GRAMPOS	2	160	TEDIZ(14); TELAV(14); DAPTO(13);	643	1072.986	11538	0.599	0.554, 0.647
				ANTIFGL	3	126	FLUCO(27); ANID(25); CASPO(25);	324	247.400	11538	1.310	1.173, 1.458
				BSHO	4	113	IMIPWC(17); MERO(16); CEFTAZ(15);	574	1844.385	11538	0.311	0.287, 0.337
				CDI	5	54	MOXI(10); CEFIX(10); CIPRO(9);	1020	2147.159	11538	0.475	0.447, 0.505
				BSCA	6	30	MOXI(9); CEFIX(9); CIPRO(9);	1090	1766.051	11538	0.617	0.581, 0.655
			WARDS	GRAMPOS	1	696	QUINWD(15); LNZ(13); OPITAV(12);	2060	3031.215	34168	0.680	0.651, 0.709

- Rank based on location group SAAR Type AU-CAD <u>within</u> the location group
- Location groups always listed in the same order

This example uses fictitious data for illustrative purposes only.

Location Group TAS Report – Combined

FACILITY			LOCATION GROUP								
Facility Org ID	Facility Name	Facility AU-CAD (Rounded)	LocationGroup	SAARTypeCat	Location Group Rank	Location Group AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	1510	WARDS	GRAMPOS	1	696	QUINWD(15); LNZ(13); ORITAV(13);	2060	3031.315	34168	0.680	0.651, 0.709
			WARDS	ANTIFGL	2	533	ANID(29); CASPO(24); MICA(24);	1031	622.127	34168	1.657	1.558, 1.761
			WARDS	BSHO	3	527	CEFTAZ(17); CEFEP(17); IMIPWC(16);	1652	4500.768	34168	0.367	0.350, 0.385
			ONCOLOGY	NSBL	4	520	AMOXWC(9); NAF(8); AMPIWS(8);	1081	509.736	10866	2.121	1.997, 2.250
			STEPDOWN	NSBL	5	395	NAF(8); CEFAD(8); DICLOX(8);	1187	720.252	11538	1.648	1.556, 1.744
			WARDS	CDI	6	323	CEFTAZ(9); CEFEP(9); MOXI(9);	3022	5997.117	34168	0.504	0.486, 0.522
			ONCOLOGY	GRAMPOS	7	177	QUINWD(16); CEFTAR(14); ORITAV(13);	632	1010.493	10866	0.625	0.578, 0.676
			STEPDOWN	GRAMPOS	8	160	TEDIZ(14); TELAV(14); DAPTO(13);	643	1072.986	11538	0.599	0.554, 0.647
			STEPDOWN	ANTIFGL	9	126	FLUCO(27); ANID(25); CASPO(25);	324	247.400	11538	1.310	1.173, 1.458
			STEPDOWN	BSHO	10	113	IMIPWC(17); MERO(16); CEFTAZ(15);	574	1844.385	11538	0.311	0.287, 0.337
			ICUS	BSCA	11	85	ERTA(9); CEFUR(9); GEMIF(8);	2764	4465.649	28864	0.619	0.596, 0.642
			WARDS	BSCA	12	56	MOXI(8); GEMIF(8); CEFPRO(8);	3252	5327.053	34168	0.610	0.590, 0.632
			STEPDOWN	CDI	13	54	MOXI(10); CEFIX(10); CIPRO(9);	1020	2147.159	11538	0.475	0.447, 0.505
			STEPDOWN	BSCA	14	30	MOXI(9); CEFIX(9); CIPRO(9);	1090	1766.051	11538	0.617	0.581, 0.655
			ONCOLOGY	BSCA	15	-6	CEFPO(9); ERTA(9); GEMIF(9);	1155	1935.253	10866	0.597	0.563, 0.632

- Rank based on location group SAAR Type AU-CAD <u>among all</u> SAAR Types and location groups

This example uses fictitious data for illustrative purposes only.

TAS Reports – Location Level

Amy Webb

Location Level TAS Report Output

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Locations
Adult SAAR Ranked by Location AU-CAD
Facility Identified SAAR Target: BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)
As of: September 26, 2022 at 11:22 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

FACILITY				LOCATION								
Facility Org ID	Facility Name	SAARTypeCat	Facility AU-CAD (Rounded)	Location	CDC Location	Location Rank	Location AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	799	AD_STP_DN	IN:ACUTE:STEP	1	328	DICLOX(9); AMOXWC(8); AMOX(8);	820	447.520	7169	1.832	1.710, 1.961
				ONCGEN	IN:ACUTE:WARD:ONC_HONC		328	AMOXWC(9); PENG(8); NAF(8);	699	337.713	7199	2.070	1.921, 2.228
				MICU	IN:ACUTE:CC:M	2	305	CEFAD(9); DICLOX(9); AMOX(9);	599	267.360	4599	2.240	2.066, 2.425
				MEDWARD	IN:ACUTE:WARD:M	3	277	CEFOX(10); AMOX(9); AMOXWC(9);	733	414.613	7132	1.768	1.643, 1.899
				MSICU	IN:ACUTE:CC:MS	4	129	AMOX(9); DICLOX(8); CEFOX(8);	579	409.001	5286	1.416	1.304, 1.535
				MEDSURG64	IN:ACUTE:WARD:MS	5	107	AMOX(8); PENV(8); AMPIWS(8);	753	587.425	7592	1.282	1.193, 1.376
				SURGWARD	IN:ACUTE:WARD:S	6	-330	AMOX(10); AMP(8); CEFOX(8);	785	1013.572	6990	0.774	0.722, 0.830
				SICU	IN:ACUTE:CC:S	7	-345	CEFOX(9); PENV(8); AMP(8);	738	984.863	6792	0.749	0.697, 0.805
		GRAMPOS	518	SURGWARD	IN:ACUTE:WARD:S	1	245	CEFTAR(13); DALBA(13); QUINWD(13);	498	562.692	6990	0.885	0.810, 0.965
				MEDWARD	IN:ACUTE:WARD:M	2	151	QUINWD(16); ORITAV(15); TELAV(13);	449	663.246	7132	0.677	0.616, 0.742
				MEDSURG64	IN:ACUTE:WARD:MS	3	127	LNZ(16); TEDIZ(14); QUINWD(12);	445	706.025	7592	0.630	0.574, 0.691
				AD_STP_DN	IN:ACUTE:STEP	4	97	LNZ(14); DAPTO(14); TELAV(14);	397	666.687	7169	0.595	0.539, 0.656
				ONCGEN	IN:ACUTE:WARD:ONC_HONC	5	95	CEFTAR(16); QUINWD(14); ORITAV(14);	396	669.477	7199	0.592	0.535, 0.652
				MICU	IN:ACUTE:CC:M	6	-48	TELAV(14); DALBA(14); QUINWD(13);	337	856.021	4599	0.394	0.353, 0.437
				SICU	IN:ACUTE:CC:S	7	-65	CEFTAR(13); ORITAV(13); TELAV(13);	504	1264.208	6792	0.399	0.365, 0.435
				MSICU	IN:ACUTE:CC:MS	8	-84	CEFTAR(16); DAPTO(14); DALBA(13);	359	983.894	5286	0.365	0.329, 0.404
		BSCA	376	SURGWARD	IN:ACUTE:WARD:S	1	198	CEFPRO(10); ERTA(9); CEFDIN(8);	719	868.733	6990	0.828	0.769, 0.890
				SICU	IN:ACUTE:CC:S	2	188	CEFOT(9); CEFPO(9); CEFUR(9);	694	844.125	6792	0.822	0.763, 0.885
				MICU	IN:ACUTE:CC:M	3	76	GEMIF(10); ERTA(10); MOXI(9);	567	819.090	4599	0.692	0.637, 0.751

This example uses fictitious data for illustrative purposes only.

Locations ranked based on Location AU-CAD value

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Locations
Adult SAAR Ranked by Location AU-CAD
Facility Identified SAAR Target: BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)

As of: September 26, 2022 at 11:22 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

FACILITY				LOCATION								
Facility Org ID	Facility Name	SAARTypeCat	Facility AU-CAD (Rounded)	Location	CDC Location	Location Rank	Location AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	799	AD_STP_DN	IN:ACUTE:STEP	1	328	DICLOX(9); AMOXWC(8); AMOX(8);	820	447.520	7169	1.832	1.710, 1.961
				ONCGEN	IN:ACUTE:WARD:ONC_HONC		328	AMOXWC(9); PENG(8); NAF(8);	699	337.713	7199	2.070	1.921, 2.228
				MICU	IN:ACUTE:CC:M	2	305	CEFAD(9); DICLOX(9); AMOX(9);	599	267.360	4599	2.240	2.066, 2.425
				MEDWARD	IN:ACUTE:WARD:M	3	277	CEFOX(10); AMOX(9); AMOXWC(9);	733	414.613	7132	1.768	1.643, 1.899
				MSICU	IN:ACUTE:CC:MS	4	129	AMOX(9); DICLOX(8); CEFOX(8);	579	409.001	5286	1.416	1.304, 1.535
				MEDSURG64	IN:ACUTE:WARD:MS	5	107	AMOX(8); PENV(8); AMPIWS(8);	753	587.425	7592	1.282	1.193, 1.376
				SURGWARD	IN:ACUTE:WARD:S	6	-330	AMOX(10); AMP(8); CEFOX(8);	785	1013.572	6990	0.774	0.722, 0.830
				SICU	IN:ACUTE:CC:S	7	-345	CEFOX(9); PENV(8); AMP(8);	738	984.863	6792	0.749	0.697, 0.805
		GRAMPOS	518	SURGWARD	IN:ACUTE:WARD:S	1	245	CEFTAR(13); DALBA(13); QUINWD(13);	498	562.692	6990	0.885	0.810, 0.965
				MEDWARD	IN:ACUTE:WARD:M	2	151	QUINWD(16); ORITAV(15); TELAV(13);	449	663.246	7132	0.677	0.616, 0.742
				MEDSURG64	IN:ACUTE:WARD:MS	3	127	LNZ(16); TEDIZ(14); QUINWD(12);	445	706.025	7592	0.630	0.574, 0.691
				AD_STP_DN	IN:ACUTE:STEP	4	97	LNZ(14); DAPTO(14); TELAV(14);	397	666.687	7169	0.595	0.539, 0.656
				ONCGEN	IN:ACUTE:WARD:ONC_HONC	5	95	CEFTAR(16); QUINWD(14); ORITAV(14);	396	669.477	7199	0.592	0.535, 0.652
				MICU	IN:ACUTE:CC:M	6	-48	TELAV(14); DALBA(14); QUINWD(13);	337	856.021	4599	0.394	0.353, 0.437
				SICU	IN:ACUTE:CC:S	7	-65	CEFTAR(13); ORITAV(13); TELAV(13);	504	1264.208	6792	0.399	0.365, 0.435
				MSICU	IN:ACUTE:CC:MS	8	-84	CEFTAR(16); DAPTO(14); DALBA(13);	359	983.894	5286	0.365	0.329, 0.404
		BSCA	376	SURGWARD	IN:ACUTE:WARD:S	1	198	CEFPRO(10); ERTA(9); CEFDIN(8);	719	868.733	6990	0.828	0.769, 0.890

This example uses fictitious data for illustrative purposes only.

Wards may be a good starting point

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Locations
Adult SAAR Ranked by Location AU-CAD
Facility Identified SAAR Target: BSHO = (0.25); BSCA = (0.6); GramPos = (0.45); NSBL = (1.1); CDI = (0.45); Antifungal = (0.8)

As of: September 26, 2022 at 11:22 AM
Date Range: All AU_TAS
if (((population = "ADULT")))

	FACILITY				LOCATION							
Facility Org ID	Facility Name	SAARTypeCat	Facility AU-CAD (Rounded)	Location	CDC Location	Location Rank	Location AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
13860	CDA-XYZ_QA_TEST FACILITY	NSBL	799	AD_STP_DN	IN:ACUTE:STEP	1	328	DICLOX(9); AMOXWC(8); AMOX(8);	820	447.520	7169	1.832	1.710, 1.961
				ONCGEN	IN:ACUTE:WARD:ONC_HONC		328	AMOXWC(9); PENG(8); NAF(8);	699	337.713	7199	2.070	1.921, 2.228
				MICU	IN:ACUTE:CC:M	2	305	CEFAD(9); DICLOX(9); AMOX(9);	599	267.360	4599	2.240	2.066, 2.425
				MEDWARD	IN:ACUTE:WARD:M	3	277	CEFOX(10); AMOX(9); AMOXWC(9);	733	414.613	7132	1.768	1.643, 1.899
				MSICU	IN:ACUTE:CC:MS	4	129	AMOX(9); DICLOX(8); CEFOX(8);	579	409.001	5286	1.416	1.304, 1.535
				MEDSURG64	IN:ACUTE:WARD:MS	5	107	AMOX(8); PENV(8); AMPIWS(8);	753	587.425	7592	1.282	1.193, 1.376
				SURGWARD	IN:ACUTE:WARD:S	6	-330	AMOX(10); AMP(8); CEFOX(8);	785	1013.572	6990	0.774	0.722, 0.830
				SICU	IN:ACUTE:CC:S	7	-345	CEFOX(9); PENV(8); AMP(8);	738	984.863	6792	0.749	0.697, 0.805
		GRAMPOS	518	SURGWARD	IN:ACUTE:WARD:S	1	245	CEFTAR(13); DALBA(13); QUINWD(13);	498	562.692	6990	0.885	0.810, 0.965
				MEDWARD	IN:ACUTE:WARD:M	2	151	QUINWD(16); ORITAV(15); TELAV(13);	449	663.246	7132	0.677	0.616, 0.742
				MEDSURG64	IN:ACUTE:WARD:MS	3	127	LNZ(16); TEDIZ(14); QUINWD(12);	445	706.025	7592	0.630	0.574, 0.691
				AD_STP_DN	IN:ACUTE:STEP	4	97	LNZ(14); DAPTO(14); TELAV(14);	397	666.687	7169	0.595	0.539, 0.656
				ONCGEN	IN:ACUTE:WARD:ONC_HONC	5	95	CEFTAR(16); QUINWD(14); ORITAV(14);	396	669.477	7199	0.592	0.535, 0.652
				MICU	IN:ACUTE:CC:M	6	-48	TELAV(14); DALBA(14); QUINWD(13);	337	856.021	4599	0.394	0.353, 0.437
				SICU	IN:ACUTE:CC:S	7	-65	CEFTAR(13); ORITAV(13); TELAV(13);	504	1264.208	6792	0.399	0.365, 0.435
				MSICU	IN:ACUTE:CC:MS	8	-84	CEFTAR(16); DAPTO(14); DALBA(13);	359	983.894	5286	0.365	0.329, 0.404
		BSCA	376	SURGWARD	IN:ACUTE:WARD:S	1	198	CEFPRO(10); ERTA(9); CEFDIN(8);	719	868.733	6990	0.828	0.769, 0.890

This example uses fictitious data for illustrative purposes only.

TAS Reports – Group Level

Laura Blum

Group TAS reports overview

- Group TAS reports similar to facility TAS reports
  - Group TAS reports display metrics pooled at the group level and for each member facility
  - All options for the facility TAS Reports are available to groups except "Combined" location groups report
- Instead of "Facility" reports, groups have "Group and Facility" reports

Group TAS Report – Group and Facility: First table

- First table is group-level summary of most recent 12 calendar months of data with additional fields available only to groups

- Interpretation of group-level metrics slightly different

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2);
Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Number of Facilities

- Number of member facilities included in group-level AU-CADs
- Member facilities that cannot generate SAARs are not included

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2); Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Number of beds

- Sum of number of beds member facilities reported in most recent Patient Safety Annual Survey included in AU-CADs

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2); Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Number of SAAR Locations

■ Number of locations eligible for inclusion in AU-CADs for each population (adult, pediatric, neonatal) and SAAR type

– Note: Neonatal FLUCO SAAR type excludes data from Level II NICUs

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2);
Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Observed and Predicted Antimicrobial Days, Days Present

- Sum of observed antimicrobial days, predicted antimicrobial days, and days present for all included member facilities

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2); Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Pooled SAAR and 95% CI

- Pooled group-level SAAR for all included facilities and associated 95% confidence interval (CI)

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2); Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Pooled AU-CAD

- AU-CAD pooled at the group-level, which uses SAAR targets set by group with sum of observed and predicted antimicrobial days for all included member facilities

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2); Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report: Three highest use drugs

- Top three antimicrobials that contributed to each SAAR type at the group level (pooled for all included member facilities)
- Does not identify how many antimicrobial days each facility contributed

National Healthcare Safety Network
TAS Report for Adult SAAR Types for Acute Care Hospitals
Total for all Facilities in Group
Group Identified SAAR Target: All antibacterials = (0.6); BSHO = (0.2); BSCA = (0.2); GramPos = (0.2); NSBL = (0.2); CDI = (0.2);
Antifungal = (0.2)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Number of Facilities	Number of Beds	Number of SAAR Locations	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
3	650	30	NSBL	61768	AMOX(74); AMOXWC(2); NAF(2);	69423	38275.687	420924	1.814	1.800, 1.827
3	650	30	GRAMPOS	26658	VANC(70); QUINWD(4); TELAV(4);	37354	53480.434	420924	0.698	0.691, 0.706
3	650	30	BSCA	5298	CEFIX(8); ERTA(8); CEFPO(8);	18180	64410.445	420924	0.282	0.278, 0.286
3	650	30	ALL	2910	AMOX(27); VANC(27); TIG(1);	186976	306777.197	420924	0.609	0.607, 0.612
3	650	30	ANTIFGL	2666	CASPO(26); ANID(25); FLUCO(25);	5459	13963.178	420924	0.391	0.381, 0.401
3	650	30	CDI	478	CEFIX(9); CLIND(9); CEFEP(9);	16905	82135.177	420924	0.206	0.203, 0.209
3	650	30	BSHO	-8993	MERO(16); CEFEP(16); IMIPWC(16);	9103	90480.072	420924	0.101	0.099, 0.103

Group TAS Report – Group and Facility: Other tables

- Subsequent tables provide metrics for each SAAR type and member facility
- Same information facilities receive in TAS Report – Facility

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Group and Facility
Facilities within the Group Ranked by AU-CAD
Group Identified SAAR Target: All antibacterials = (0.6)
As of: September 22, 2022 at 2:42 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Facility Rank	Facility Org ID	Facility Name	State	Medical School Affiliation	Number of Beds	SAARTypeCat	Facility AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	95% Confidence Interval
1	10036	TESTING FACILITY	GA	M	200	ALL	1582	CEFOX(2); PIPERWT(2); CEFTAR(2);	17402	26366.768	36261	0.660	0.650, 0.670
2	10000	DHQP MEMORIAL HOSPITAL	GA	M	300	ALL	1010	TINID(2); CEFIX(2); ERTA(2);	19319	30514.798	41240	0.633	0.624, 0.642
3	33617	_CDA-XYZ TEST FACILITY (PROD)	GA	M	150	ALL	318	AMOX(34); VANC(33); TIG(1);	150255	249895.631	343423	0.601	0.598, 0.604

Group TAS Report – Location Groups (Separated)

- Same information facilities receive in TAS Report – Location Groups (Separated) for each member facility

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Location Groups (Separated)
Adult All Antibacterials SAAR Location Groups Ranked by AU-CAD
Facility Identified SAAR Target: All Antibacterials = (0.6) ←
As of: September 22, 2022 at 2:44 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

For group Location Groups and Locations reports, first table is ALL SAAR type and second table contains the other SAAR types

FACILITY				LOCATION GROUP									
Facility Org ID	Facility Name	Facility AU-CAD (Rounded)	LocationGroup	SAARTypeCat	Location Group Rank	Location Group AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval	
10000	DHQP MEMORIAL HOSPITAL	1010	WARDS	ALL	1	1913	MOXI(2); CEFIX(2); ERTA(2);	9309	12325.913	20250	0.755	0.740, 0.771	
			STEPDOWN	ALL	2	402	QUINWD(2); CEFEP(2); METRO(2);	1123	1201.911	2017	0.934	0.881, 0.990	
			ONCOLOGY	ALL	3	162	MERO(2); SULFAET(2); NAF(2);	1104	1569.560	2515	0.703	0.663, 0.746	
			ICUS	ALL	4	-1467	RIF(2); TINID(2); LEVO(2);	7783	15417.414	16458	0.505	0.494, 0.516	
10036	TESTING FACILITY	1582	WARDS	ALL	1	1719	CEFPRO(2); CEFAD(2); CEFOX(2);	7851	10219.453	17170	0.768	0.751, 0.785	
			STEPDOWN	ALL	2	330	CEFTAZ(2); CEFTAVI(2); PB(2);	1096	1277.084	2175	0.858	0.809, 0.910	
			ONCOLOGY	ALL	3	239	QUINWD(3); NAF(2); AMP(2);	1143	1506.138	2439	0.759	0.716, 0.804	
			ICUS	ALL	4	-706	CEFTAR(2); CEFIX(2); CEFTAVI(2);	7312	13364.093	14477	0.547	0.535, 0.560	
33617	_CDA-XYZ TEST FACILITY (PROD)	320	WARDS	ALL	1	39016	AMOX(58); VANC(21); MINO(0);	87015	79990.984	132981	1.088	1.081, 1.095	
			ONCOLOGY	ALL	2	-1490	VANC(49); AZITH(1); ERTA(1);	12655	23575.247	37025	0.537	0.527, 0.546	
			STEPDOWN	ALL	3	-1790	VANC(51); IMIPWC(1); TINID(1);	13361	25250.982	42119	0.529	0.520, 0.538	
			ICUS	ALL	4	-35416	VANC(51); TIG(1); CEFEP(1);	37224	121078.418	131298	0.307	0.304, 0.311	

Group TAS Report – Locations

- Same information facilities receive in TAS Report – Locations for each SAAR eligible location within member facilities

National Healthcare Safety Network
TAS Report - Adult SAAR Types - Locations
Adult All Antibacterials SAAR Ranked by Location AU-CAD
Facility Identified SAAR Target: All Antibacterials = (0.6)
As of: September 22, 2022 at 2:47 PM
Date Range: All AU_TAS
if (((population = "ADULT")))

Note: Report may be long if member facilities have many SAAR eligible locations mapped

		FACILITY					LOCATION						
Facility Org ID	Facility Name	SAARTypeCat	Facility AU-CAD (Rounded)	Location	CDC Location	Location Rank	Location AU-CAD (Rounded)	Three highest use drugs within SAAR Type (Percentage)	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	Location SAAR	95% Confidence Interval
10000	DHQP MEMORIAL HOSPITAL	ALL	1009	MD WARD	IN:ACUTE:WARD:M	1	740	CEFIX(2); CEFTAZ(2); LEVO(2);	2871	3551.697	5926	0.808	0.779, 0.838
				17N	IN:ACUTE:WARD:S	2	658	DICLOX(2); AMP(2); CEFEP(2);	2879	3701.458	5977	0.778	0.750, 0.807
				AD_STP_DN	IN:ACUTE:STEP	3	402	QUINWD(2); CEFEP(2); METRO(2);	1123	1201.911	2017	0.934	0.881, 0.990
				MEDSURG64	IN:ACUTE:WARD:MS	4	224	RIF(2); CEFTAZ(2); CEPHLX(2);	1167	1572.105	2599	0.742	0.701, 0.786
				ONCGEN	IN:ACUTE:WARD:ONC_HONC	5	162	MERO(2); SULFAET(2); NAF(2);	1104	1569.560	2515	0.703	0.663, 0.746
				MEDWARD	IN:ACUTE:WARD:M	6	154	ERTA(3); PENG(2); CEFIX(2);	1218	1772.852	2958	0.687	0.649, 0.726
				SURGWARD	IN:ACUTE:WARD:S	7	137	CEPHLX(2); CEFAC(2); CEFUR(2);	1174	1727.801	2790	0.679	0.641, 0.719
				MSICU	IN:ACUTE:CC:MS	8	-242	DAPTO(3); DALBA(2); FOSFO(2);	1100	2236.074	2492	0.492	0.464, 0.522
				MICU-2B	IN:ACUTE:CC:M	9	-298	TINID(2); AMP(2); OX(2);	2728	5043.160	5301	0.541	0.521, 0.562
				MICU	IN:ACUTE:CC:M	10	-382	PIPERWT(3); FIDAX(2); LEVO(2);	1117	2498.273	2626	0.447	0.421, 0.474
				SICU	IN:ACUTE:CC:S	11	-546	CEFPO(2); RIF(2); GEMIF(2);	2838	5639.907	6039	0.503	0.485, 0.522
10036	TESTING FACILITY	ALL	1582	INWARDMED	IN:ACUTE:WARD:M	1	735	PB(2); PENV(2); AMOXWC(2);	2218	2471.281	4180	0.898	0.861, 0.935
				INSURG	IN:ACUTE:WARD:S	2	419	CEFAD(2); TETRA(2); DICLOX(2);	2242	3037.608	5071	0.738	0.708, 0.769
				AD_STP_DN	IN:ACUTE:STEP	3	330	CEFTAZ(2); CEFTAVI(2); PB(2);	1096	1277.084	2175	0.858	0.809, 0.910
				MEDWARD	IN:ACUTE:WARD:M	4	280	PENG(3); CEFPRO(2); CEFTRX(2);	1153	1455.573	2462	0.792	0.747, 0.839

TAS Dashboard

Laura Blum

TAS Dashboard overview

- Allows NHSN facilities to visualize locations with the greatest need for antimicrobial stewardship

- Displays AU-CADs over time, by quarter, for most recent complete four calendar quarters at the facility and location level

- Unlike TAS Reports, users cannot change the time period and level of aggregation displayed

Accessing the TAS Dashboard

- Located on NHSN Patient Safety Component Home Page or by navigating to Dashboard and then TAS Dashboard from the left-hand menu in NHSN

TAS Dashboard set-up: Generate data sets

- Generate New button generates data sets for <u>all</u> NHSN Patient Safety Component modules just like navigating to Analysis and then Generate Data Sets from the left-hand menu

- Last Generated date displays the last time you ran a data set generation

- Always generate new data sets after uploading data into NHSN

TAS Dashboard set-up: Population

- Population drop-down menu displays the TAS Dashboard for each population (adult, pediatric, or neonatal)
  - Only one population displayed at a time
  - Adult population selected by default

TAS Dashboard set-up: SAAR targets

- Same as SAAR targets used for the TAS Reports
  - Unique to your NHSN user account, can be changed at any time
- TAS Dashboard displays AU-CAD data based on the SAAR targets you entered when you click Save
- For this example, we entered SAAR targets of 0.40 for each SAAR type

TAS Dashboard display

Facility AU TAS Report Dashboard by Quarter

TAS Dashboard: Y-Axis

Facility AU TAS Report Dashboard by Quarter

Displays numeric AU-CAD value; automatically adjusts to accommodate the range of AU-CAD values for your facility, including values above and below zero

TAS Dashboard: X-Axis

Facility AU TAS Report Dashboard by Quarter

Displays abbreviation for each SAAR type available for the selected population (full names of SAAR Types can be found in TAS Dashboard footnotes)

TAS Dashboard: Graph

Facility AU TAS Report Dashboard by Quarter

Graphical interpretation of AU-CADs for each SAAR type over time by quarter for the most recent complete four calendar quarters at the facility level

TAS Dashboard: No Data (ND)

Facility AU TAS Report Dashboard by Quarter

AU-CAD values only appear if you've entered a SAAR target and have uploaded AU data for locations that can generate SAARs; "ND" indicates no data are available for that SAAR type/quarter combination or an AU-CAD for the specific SAAR type/quarter cannot be generated

TAS Dashboard: Interpretation

To reduce our 2021Q2 adult GRAMPOS SAAR to SAAR target of 0.40, we would have needed to reduce use of adult antibacterial agents predominantly used for resistant Gram-positive infections at our facility by at least 482 antimicrobial days.

TAS Dashboard: Table

- Table below TAS Dashboard graph repeats information from the graph in tabular format

Facility AU-CAD				
SAAR Type	2021Q2	2021Q3	2021Q4	2022Q1
ALL	ND	5717	ND	5147
BSHO	-821	-1454	-1321	-700
BSCA	1195	1195	971	975
GRAMPOS	482	435	323	408
NSBL	2152	2321	ND	1850
CDI	550	276	201	445
ANTIFGL	570	588	603	423

Accessing the TAS Dashboard drilldown

Facility AU TAS Report Dashboard by Quarter

Click the colored bar (shown below) or the number above/below the bar to access the TAS Dashboard drilldown for each SAAR type and quarter combination

TAS Dashboard drilldown

TAS Dashboard drilldown: Back button

Click to return to the TAS Dashboard

Number of Antimicrobial Days to Reduce to Reach Facility Specific SAAR

TAS Dashboard drilldown: Y-Axis

TAS Dashboard drilldown: X-Axis

This example uses fictitious data for illustrative purposes only.

Displays numeric AU-CAD value for each location; automatically adjusts to accommodate the range of AU-CAD values for your locations, including values above and below zero

TAS Dashboard drilldown: Graph

GRAMPOS SAAR Number of Antimicrobial Days to Reduce to Reach Facility Specific SAAR

Displays graphical interpretation of the AU-CADs for each eligible location for the selected SAAR type and quarter, ordered by AU-CAD from highest to lowest

This example uses fictitious data for illustrative purposes only.

TAS Dashboard drilldown: Interpretation

TAS Dashboard drilldown: Table

- Table below TAS Dashboard drilldown graph repeats information from the graph with the addition of observed antimicrobial days, predicted antimicrobial days, and three highest use drugs within the SAAR type/quarter combo for each location

SAAR Type	Summary Year/Quarter	Location Rank	Location	Location Code	AU Days Predicted	Observed Antimicrobial Days	Location AU-CAD	Three highest use drugs within SAAR Type
GRAMPOS	2021Q2	1	MEDSURG64	IN:ACUTE:WARD:MS	325.114	245	115	CEFTAR(14); DALBA(14); ORITAV(14);
		2	ONCGEN	IN:ACUTE:WARD:ONC_HONC	321.301	239	110	CEFTAR(16); DALBA(16); ORITAV(14);
		3	SURGWARD	IN:ACUTE:WARD:S	281.105	216	104	DAPTO(17); DALBA(15); TEDIZ(15);
		4	AD_STP_DN	IN:ACUTE:STEP	361.01	236	92	ORITAV(15); LNZ(14); TELAV(13);
		5	MEDWARD	IN:ACUTE:WARD:M	282.987	204	91	TEDIZ(16); CEFTAR(14); ORITAV(14);
		6	SICU	IN:ACUTE:CC:S	466.633	202	15	DAPTO(15); LNZ(15); CEFTAR(14);
		7	MICU	IN:ACUTE:CC:M	575.707	243	13	CEFTAR(17); LNZ(15); TEDIZ(13);
		8	MSICU	IN:ACUTE:CC:MS	647.553	202	-57	QUINWD(16); LNZ(15); ORITAV(14);

TAS Dashboard drilldown: Three highest use drugs

- Displays top three antimicrobials that contributed to the selected SAAR antimicrobial category for the selected quarter for each location and, in parenthesis, the percent of observed antimicrobial days each antimicrobial contributed rounded to the nearest whole number

  - Drug names abbreviated with NHSN drug codes; full drug names can be found in the [AUR Module Eligible Antimicrobial Agents spreadsheet](#)

  - If two or more antimicrobials contributed the same observed antimicrobial days, they are listed in alphabetical order by drug code

SAAR Type	Summary Year/Quarter	Location Rank	Location	Location Code	AU Days Predicted	Observed Antimicrobial Days	Location AU-CAD	Three highest use drugs within SAAR Type
GRAMPOS	2021Q2	1	MEDSURG64	IN:ACUTE:WARD:MS	325.114	245	115	CEFTAR(14); DALBA(14); ORITAV(14);
		2	ONCGEN	IN:ACUTE:WARD:ONC_HONC	321.301	239	110	CEFTAR(16); DALBA(16); ORITAV(14);
		3	SURGWARD	IN:ACUTE:WARD:S	281.105	216	104	DAPTO(17); DALBA(15); TEDIZ(15);
		4	AD_STP_DN	IN:ACUTE:STEP	361.01	236	92	ORITAV(15); LNZ(14); TELAV(13);
		5	MEDWARD	IN:ACUTE:WARD:M	282.987	204	91	TEDIZ(16); CEFTAR(14); ORITAV(14);

Three highest use drugs: Interpretation

- CEFTAR, DALBA, and ORITAV tied as most frequently administered antimicrobials in the adult GRAMPOS antimicrobial category for MEDSURG64 in 2021Q2 so they are listed in alphabetical order by drug code

- CEFTAR, DALBA, and ORITAV each contributed 14% of the observed 245 antimicrobial days

SAAR Type	Summary Year/Quarter	Location Rank	Location	Location Code	AU Days Predicted	Observed Antimicrobial Days	Location AU-CAD	Three highest use drugs within SAAR Type
GRAMPOS	2021Q2	1	MEDSURG64	IN:ACUTE:WARD:MS	325.114	245	115	CEFTAR(14); DALBA(14); ORITAV(14);
		2	ONCGEN	IN:ACUTE:WARD:ONC_HONC	321.301	239	110	CEFTAR(16); DALBA(16); ORITAV(14);
		3	SURGWARD	IN:ACUTE:WARD:S	281.105	216	104	DAPTO(17); DALBA(15); TEDIZ(15);
		4	AD_STP_DN	IN:ACUTE:STEP	361.01	236	92	ORITAV(15); LNZ(14); TELAV(13);
		5	MEDWARD	IN:ACUTE:WARD:M	282.987	204	91	TEDIZ(16); CEFTAR(14); ORITAV(14);
		6	SICU	IN:ACUTE:CC:S	466.633	202	15	DAPTO(15); LNZ(15); CEFTAR(14);
		7	MICU	IN:ACUTE:CC:M	575.707	243	13	CEFTAR(17); LNZ(15); TEDIZ(13);
		8	MSICU	IN:ACUTE:CC:MS	647.553	202	-57	QUINWD(16); LNZ(15); ORITAV(14);

TAS Dashboard for groups

- NHSN groups can also use TAS Dashboard to visualize overall AU-CADs for the group and member facilities
  - Group TAS Dashboard displays AU-CADs pooled at the group level
  - Clicking into the drilldown allows groups to view cumulative AU-CADs for each member facility
- All options for the facility TAS Dashboard are available to groups except location-level data and top three highest drugs
  - These options *are* available in the group TAS reports
- Interpretation of group-level AU-CADs slightly different

TAS Dashboard for groups: Set-up

- SAAR targets function similarly at the group and facility level

- Special considerations for groups:

  - Groups cannot set different SAAR targets for each member facility

  - Setting SAAR targets at the group level does not affect member facilities' SAAR targets or SAAR data

- For this example, we entered SAAR targets of 1.2 for the adult ALL SAAR type and 0.2 for everything else

TAS Dashboard for groups display

Group AU TAS Report Dashboard by Quarter

This example uses fictitious data for illustrative purposes only.

TAS Dashboard for groups: Interpretation

For member facilities to collectively reduce their 2021Q3 adult BSHO SAARs to meet our SAAR target of 0.20, they would have needed to reduce use of adult BSHO agents by at least 449 antimicrobial days.

TAS Dashboard drilldown for groups display

BSHO SAAR Number of Antimicrobial Days to Reduce to Reach Group Specific SAAR

TAS Dashboard drilldown for groups: Y-Axis

BSHO SAAR Number of Antimicrobial Days to Reduce to Reach Group Specific SAAR

Displays Facility ID (orgID) for each member facility NHSN calculated an AU-CAD for

TAS Dashboard drilldown for groups: Interpretation

BSHO SAAR Number of Antimicrobial Days to Reduce to Reach Group Specific SAAR

OrgID 10036 had highest adult BSHO AU-CAD among the included member facilities in 2021Q3. To reduce their 2021Q3 adult BSHO SAAR to SAAR target of 0.20, the facility would have needed to reduce use of adult BSHO agents by approximately 259 antimicrobial days.

Assess & Steward

Melinda Neuhauser

Assess: Utilize assessment tools to identify gaps and opportunities to improve antimicrobial use

- Select the assessment approach that best aligns with the facility priorities, resources and stewardship activities

  - Comprehensiveness of Antimicrobial Stewardship Program

    - NHSN Annual Hospital Survey

    - Antibiotic Stewardship Program Assessment Tool

  - Identification of opportunities to improve antimicrobial use

    - Strategies to Assess Antibiotic Use to Drive Improvements in Hospitals

    - Appropriate use assessment such as medication use evaluations

Assessment tool: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/assessment-tool-P.pdf
Strategies: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/Strategies-to-assess-antibiotic-use-in-hospitals-508.pdf

Assess: Identify gaps and opportunities to improve antimicrobial use

- Once the assessments have been completed, the findings can be summarized and presented to the antimicrobial stewardship committee and/or other hospital committees, such as Pharmacy and Therapeutics.

  - The assessment may determine that use is appropriate based upon local guidelines and practices.

Steward: Implement antimicrobial stewardship activities to address gaps and opportunities to improve antibiotic use

- Once the findings have been summarized and presented as part of the assessment, the antimicrobial stewardship program can embark on planning and implementing antimicrobial stewardship activities addressing the identified gaps and opportunities.

- TAS guide includes CDC stewardship resources for facilities to expand components of their antimicrobial stewardship program.

The TAS framework consists of three components:

1. **Target:** Run TAS Reports in NHSN to identify facilities, location groups and locations for further assessment using the ranked AU cumulative attributable difference (AU-CAD).

2. **Assess:** Utilize assessment tools to identify gaps and opportunities to improve antibiotic use.

3. **Steward:** Implement antibiotic stewardship activities to address gaps and opportunities.

TAS Resources

- NHSN's TAS Guide: https://www.cdc.gov/nhsn/ps-analysis-resources/tas/tas-guide-508.pdf

- AUR Module Analysis Quick Reference Guides: https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html#accordion-1-collapse-5

- AUR Module Protocol: https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf

- AUR Training: https://www.cdc.gov/nhsn/training/patient-safety-component/aur.html

Q & A

Q & A

- Type your questions into the Q&A box

- Questions not answered today can be directed to NHSN:
  - Protocol & submission questions: NHSN@cdc.gov
  - CDA submission & troubleshooting questions: NHSNCDA@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348   www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.